F S&P 500
5,124.50 +42.25 (+0.83%) F Dow Jones
38,330.00 +42.00 (+0.11%) F Nasdaq
17,775.75 +208.25 (+1.19%) E-mini Russell 2000 Index Futur
1,989.10 -4.10 (-0.21%) Petróleo
83.82 +0.25 (+0.30%) Oro
2,345.10 +2.60 (+0.11%)
XBiotech Inc. (XBIT)
XBiotech Inc.
5217 Winnebago Lane
Austin, TX 78744
United States
512 386 2900
https://www.xbiotech.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 82
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. John Simard | Founder, President, CEO & Chairman | 5.56M | N/D | 1962 |
| Dr. Sushma Shivaswamy Ph.D. | Chief Scientific Officer | 449.99k | N/D | 1978 |
| Ms. Angela Hu | Director of Finance, Principal Financial & Accounting Officer and Financial Controller | 198.13k | N/D | 1984 |
Descripción
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Gestión corporativa
La calificación ISS Governance QuickScore de XBiotech Inc. a partir del 1 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 9; Junta: 7; Derechos del accionista: 5; Compensación: 9.
